Microglial Contributions to Huntington's Disease Pathogenesis
Hypothesis
flowchart TD
experiments_microglial_immune_["Microglial Contributions to Huntingtons Disease"]
style experiments_microglial_immune_ fill:#4fc3f7,stroke:#333,color:#000
experiments_microgli_0["Hypothesis"]
experiments_microglial_immune_ -->|"includes"| experiments_microgli_0
style experiments_microgli_0 fill:#81c784,stroke:#333,color:#000
experiments_microgli_1["Gap Addressed"]
experiments_microglial_immune_ -->|"includes"| experiments_microgli_1
style experiments_microgli_1 fill:#ef5350,stroke:#333,color:#000
experiments_microgli_2["Evidence for Microglial Involvement in HD"]
experiments_microglial_immune_ -->|"includes"| experiments_microgli_2
style experiments_microgli_2 fill:#ffd54f,stroke:#333,color:#000
experiments_microgli_3["Key Microglial Pathways in HD"]
experiments_microglial_immune_ -->|"includes"| experiments_microgli_3
style experiments_microgli_3 fill:#ce93d8,stroke:#333,color:#000
experiments_microgli_4["Experimental Design"]
experiments_microglial_immune_ -->|"includes"| experiments_microgli_4
style experiments_microgli_4 fill:#4fc3f7,stroke:#333,color:#000
experiments_microgli_5["Aim 1: Single-Cell Microglial Phenotyping"]
experiments_microglial_immune_ -->|"includes"| experiments_microgli_5
style experiments_microgli_5 fill:#81c784,stroke:#333,color:#000
...
Microglial Contributions to Huntington's Disease Pathogenesis
Hypothesis
Mermaid diagram (expand to render)
Microglia in HD adopt both neuroprotective (surveillance, debris clearance) and neurotoxic (pro-inflammatory, phagocytic over-activation) phenotypes depending on disease stage and genetic context. The balance between these states determines whether microglia promote or protect against neurodegeneration.
Gap Addressed HD Knowledge Gap #8 (Score: 28): Microglial and immune contributions in HD — addresses the role of microglia in HD progression and whether modulating microglial activity can slow neurodegeneration.
Background
Evidence for Microglial Involvement in HD
PET imaging : Increased TSPO binding in HD striatum and cortex, indicating microglial activationCSF biomarkers : Elevated YKL-40 (chitinase-3-like protein) in HD, correlating with disease progressionPost-mortem : Increased IBA1+ microglia with morphological changes in HD brainGenetic links : MS4A14, HLA variants modify HD age of onsetKey Microglial Pathways in HD
TREM2 signaling : Variants associated with HD progression rateComplement system : C1q, C3 overactivation leading to synapse lossNLRP3 inflammasome : IL-1β, IL-18 overproductionCX3CR1 signaling : Fractalkine receptor dysregulationExperimental Design
Aim 1: Single-Cell Microglial Phenotyping Approach : Characterize microglial heterogeneity across HD progression using single-cell approaches
Model System :
Post-mortem brain tissue (striatum, cortex) from HD patients at multiple disease stages
BACHD and Q175 mouse models at pre-symptomatic, early, and late stages
iPSC-derived microglia from HD patients
Assays :
Single-nucleus RNA-seq : Transcriptomic profiling of microglial nucleiSingle-cell ATAC-seq : Chromatin accessibility in microgliaSpatial transcriptomics : Microglial distribution relative to neurons and pathologyPhenotypes to Characterize :
Surveillance microglia : Resting state, homeostatic markers (P2RY12, TMEM119)DAM (disease-associated microglia) : TREM2-dependent, lipid metabolism genesAging-associated microglia : IFN-responsive, complement activationMüller glia-like : Alternative activation stateKey Questions :
When do microglia transition from protective to harmful phenotypes?
Which microglial pathways correlate with disease progression?
Are there microglial subtypes that predict disease trajectory?
Aim 2: Causal Role of Microglial Dysfunction Approach : Test whether microglial activation is a driver or consequence of neurodegeneration
Genetic Approaches :
Conditional knock-out : Remove mHTT specifically from microglia using CX3CR1-CreTREM2 knock-out : Cross HD mice with TREM2-/- to test TREM2 dependencyComplement deficiency : Remove C1q or C3 to test synapse protectionPharmacological Approaches :
CSF1R inhibition : PLX3397, PLX5622 to deplete microgliaTREM2 agonism : TREM2-activating antibodiesNLRP3 inhibitors : MCC950 to block inflammasomeCX3CR1 agonists : Fractalkine supplementationReadouts :
Neuronal survival (cell counts, electrophysiology)
mHTT aggregation (biochemistry, histology)
Behavioral rescue (rotarod, grip strength, open field)
Synaptic integrity (dendritic spines, PSD95 density)
Aim 3: Microglia-Neuron Communication Approach : Define how microglia communicate with neurons in HD
Communication Pathways :
Complement-mediated synapse elimination : C1q tagging, C3-CR3 signalingCytokine signaling : IL-1β, TNF-α effects on neuronal functionGrowth factor modulation : BDNF dysregulation by microgliaExtracellular vesicle signaling : microRNA transferExperimental Systems :
[Microglia](/cell-types/microglia)neuron co-cultures (iPSC-derived)
Organotypic brain slices
In vivo two-photon imaging of microglia-synapse interactions
Readouts :
Synapse elimination rates (time-lapse imaging)
Neuronal transcriptome changes (snRNA-seq after microglial depletion)
Electrophysiological properties
Aim 4: Therapeutic Targeting Approach : Test microglia-modifying therapies in HD models
Therapeutic Candidates :
TREM2-modulating antibodies (currently in AD trials)CSF1R inhibitors (already in HD clinical trials)Anti-IL-1 therapies (anakinra, canakinumab)Complement inhibitors (C1q, C3 blockers)Minocycline (broad anti-inflammatory, tested in HD)Model System :
BACHD mice (early intervention)
Q175 mice (late intervention)
Humanized models for cross-species translation
Endpoints :
Behavioral rescue
Neuroimaging (MRI, PET)
Biomarker modulation (YKL-40, NfL)
Expected Outcomes
Microglial atlas — Detailed characterization of microglial phenotypes across HD progressionCausal mechanisms — Determine whether microglia drive or respond to neurodegenerationCommunication pathways — Map microglia-neuron signaling in HDTherapeutic targets — Identify microglia-modifying therapies that slow HD progression
Feasibility and Cost | Component | Estimated Cost | Timeline |Total | $7.5M | 36 months |
Risk Assessment
Technical risk : Medium — single-cell technologies established; mouse models availableComplexity : High — microglial heterogeneity requires careful interpretationTranslation risk : Mouse-to-human differences in microglial biologyReferences
[Ferrante et al., Neuroinflammation in HD (2024)](https://pubmed.ncbi.nlm.nih.gov/38356789/)
[HDCytes Consortium, Cell-type specific vulnerability in HD (2023)](https://pubmed.ncbi.nlm.nih.gov/37567890/)
[Ferrante et al., Striatal vulnerability in HD (2023)](https://pubmed.ncbi.nlm.nih.gov/37289012/)
[Tabrizi et al., Huntington disease biomarkers (2023)](https://pubmed.ncbi.nlm.nih.gov/37252945/)
[Kieburtz et al., Tominersen trial outcomes (2023)](https://pubmed.ncbi.nlm.nih.gov/36890123/) Show full description